Navigation Links
Pest Control research Leads to Pain Control Discovery

Researchers have claimed that studies that were being conducted towards pest control have lead to the discovery of pain control. //

Researchers from the University of California, have stated that the newly discovered enzyme inhibitor, which earlier had been identified by researchers who were initially looking for biological pest controls, might actually lead to pain relief for people suffering from arthritis and other inflammatory diseases. It has been reported that a noted inflammatory disease expert has acknowledged the discovery as the most important discovery in inflammation in more than a decade, and was of the opinion that it might also reduce side effects associated with the painkiller, Vioxx.

Lead author Kara Schmelzer, a post-doctoral researcher in principal investigator Bruce Hammock's lab, tested the novel compounds on rodents and found them to be as potent at a low-dose as Vioxx and Celebrex, but without the changes in blood chemistry linked to heart attacks. Vioxx and Celebrex belong to a class of drugs known as Cox-2 inhibitors. The enzyme targeted by the newly discovered inhibitors is also found in humans. (Enzymes are proteins that speed up chemical reactions.)

'The reason this is so exciting is that this is a novel way to reduce inflammation, with a combination therapy,' Schmelzer said. 'We're going after a new enzyme target, not going after the Cox-2 inhibitors.'

Their research is reported in a paper entitled 'Enhancement of Antinociception by Co administration of Nonsteroidal Anti-Inflammatory Drugs and Soluble Epoxide Hydrolase Inhibitors,' published in the current edition of Proceedings of the National Academy of Sciences.

'Our laboratory was initially interested in regulating the development of insect larvae,' said Hammock, a distinguished professor of entomology and member of the National Academy of Sciences.” The discovery switched the focus of the research from ‘pest control to pain control’.

M. Eric Gershwin, chief of the Division of Rheumatology, Allergy and Clinical Immunology at the UC Davis School of Medicine and a distinguished professor of medicine, called the discovery 'the most important discovery in inflammation in more than a decade.' Gershwin, who was not affiliated with this study, is noted for his research on rheumatoid arthritis and other inflammatory diseases. His lab investigates the mechanisms leading to immunological alterations and autoimmunity.

As of 2004, physicians prescribed anti-inflammatory medication for more than 73 million patients. But many of the people suffer from pharmacological properties or side effects of the medications. Merck, the pharmaceutical company that manufactured and marketed Vioxx, a Cox-2 selective nonsteroidal anti-inflammatory drug (NSAID), voluntarily pulled the pain killer from the market in September 2004 due to safety concerns. A 12-month study, published in 2000, showed a four-fold increased risk of heart attacks. Merck hopes to replace it with another medication, Acoxia.

However, the class of drugs benefits millions of sufferers from inflammation and pain, Hammock said. The UC Davis study may mean a solution to the dilemma of whether to use the drugs.

'Combination therapies have long been used to treat inflammation while reducing side effects,' Schmelzer wrote. She said the present study was designed to evaluate the therapeutic potential of combination treatment with NSAIDs and enzyme inhibitors (a previously undescribed soluble epoxide hydrolase inhibitor or sEHIs) in lipopolysaccharide (LPS)-challenged mice.

'We used LPS as an inflammatory agent, which is a component of some bacterial cell walls,' said, co-author Steven Jinks. His laboratory examined the effects of these compounds in rodent inflammatory pain behavior models. 'Inflammatory mediators sensitize pain receptors and cause the animal to withdraw more quickly from a nox ious stimulus, an indication of 'hyperalgesia' or heightened response to a painful stimulus.' The sEH inhibitors reverse hyperalgesia and bring their withdrawal reaction back into the normal range.

Hammock said 'these sEHIs are of similar or greater potency in reducing inflammation in rodents to Vioxx, but also when combined with Vioxx can dramatically reduce the concentrations of the Cox 2 inhibitor needed,' Hammock said.

'The combination of Vioxx with the new sEHIs shifts blood chemistry toward the normal condition which may reduce the tendency toward blood clots,' said UC Davis scientist Bora Inceoglu, a post-doctoral researcher and member of the research team.
VK
'"/>




Related medicine news :

1. FDA Approves Birth Control Skin Patch
2. Control of inflammation
3. New Birth Control Pills increase the stroke risk
4. Control of anger disorder connected to Brain Dysfunction
5. WHO Declares Vietnam First Country to Control SARS
6. The Importance Of “ Good ”Control Of Diabetes During Pregnanc
7. Controlling Asthma during Pregnancy
8. Effective Control Of Blood Sugar Levels
9. Controlling Allergies Before They Start
10. Diabetics Can Now Be Able To Control Both Blood Sugar And Their Weight
11. Better Control Of Sugar Levels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/2/2016)... ... , ... Over $60 Billion is spent annually on products for our favorite ... review site for Toys, Tots, Pets & More (TTPM) announced the 15 winners of ... the Metropolitan Pavilion in New York City. , Chosen from a field of hundreds ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Further establishing itself ... announce that the new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants ... Showcase Award. , WHIMZEES natural dental chews for dogs are a favorite product ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Sixth Annual Lifestyle Intervention ... Bellagio Hotel in Las Vegas, NV from October 17–19, 2016. The Nevada ... event. , This year’s conference will offer presentations featuring new treatment tracks, ...
(Date:5/2/2016)... ... , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city ... “ 5 US Cities with the Highest Plastic Rates .” The other cities that ... were calculated using a survey by RealSelf and combining that data with the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Research and Markets has announced ... Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected to ... 2016-2020. , ,The growing adoption of laser in aesthetics ... the market. Lasers are used to treat a broad ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
Breaking Medicine Technology: